Limits...
Correction: Novel Synthetic Oxazines Target NF- κ B in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo

View Article: PubMed Central - PubMed

No MeSH data available.


HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.Histogram obtained indicated the accumulation cells in sub-G1 phase.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5383341&req=5

pone.0175659.g001: HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.Histogram obtained indicated the accumulation cells in sub-G1 phase.

Mentions: Fig 2 appears incorrectly in the published article. Please see the correct Fig 2 and its caption here.


Correction: Novel Synthetic Oxazines Target NF- κ B in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo
HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.Histogram obtained indicated the accumulation cells in sub-G1 phase.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5383341&req=5

pone.0175659.g001: HCT116 cells were treated with different doses of API (0.5, 1, 5, and 10 μM) for 48 h, harvested and stained with propidium iodide and subjected to flow cytometry.Histogram obtained indicated the accumulation cells in sub-G1 phase.
Mentions: Fig 2 appears incorrectly in the published article. Please see the correct Fig 2 and its caption here.

View Article: PubMed Central - PubMed

No MeSH data available.